0001209191-20-027476.txt : 20200506 0001209191-20-027476.hdr.sgml : 20200506 20200506162735 ACCESSION NUMBER: 0001209191-20-027476 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200504 FILED AS OF DATE: 20200506 DATE AS OF CHANGE: 20200506 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Silva Paul M CENTRAL INDEX KEY: 0001446372 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 20853004 MAIL ADDRESS: STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-05-04 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001446372 Silva Paul M C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 SVP & Controller Common Stock 2020-05-04 4 M 0 809 86.52 A 15741 D Common Stock 2020-05-04 4 S 0 200 259.21 D 15541 D Common Stock 2020-05-04 4 S 0 250 259.97 D 15291 D Common Stock 2020-05-04 4 S 0 200 261.55 D 15091 D Common Stock 2020-05-04 4 S 0 100 262.83 D 14991 D Common Stock 2020-05-04 4 S 0 59 264.75 D 14932 D Common Stock 169 I 401(k) Stock Option (Right to Buy) 86.52 2020-05-04 4 M 0 809 0.00 D 2027-02-02 Common Stock 809 2427 D Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $259.21 (range $258.62 to $259.60). Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $259.97 (range $259.72 to $260.33). Open market sales reported on this line occurred at a weighted average price of $261.55 (range $261.13 to $262.11). Open market sales reported on this line occurred at a weighted average price of $262.83 (range $262.74 to $262.92). Open market sales reported on this line occurred at a weighted average price of $264.75 (range $264.59 to $264.89). The option vests in 16 quarterly installments from 02/03/2017. /s/ Sabrina Yohai, Attorney-in-Fact 2020-05-06